Previous 10 | Next 10 |
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043 - Completed enrollment for the Phase 1a clinical trial in chronic liver disease patients and healthy volunteers - Expect to announce Phase 1a safety and ...
2023-11-09 08:42:21 ET More on Surrozen Seeking Alpha’s Quant Rating on Surrozen Historical earnings data for Surrozen Financial information for Surrozen For further details see: Surrozen GAAP EPS of -$0.34 misses by $0.03
Surrozen Inc. (SRZN) is expected to report $-0.28 for Q3 2023
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initiating Phase 1b studies in 2024 for SZN-043...
2023-08-10 14:32:01 ET Surrozen press release ( NASDAQ: SRZN ): Q2 GAAP EPS of -$0.31 Cash, cash equivalents and marketable securities for the second quarter ended June 30, 2023 were $53.4 million, compared to $61.7 million as of March 31, 2023. For further detai...
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 ...
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while improving neurologic score Results highlight potential of selective Fzd4 Wnt antibody for cen...
2023-05-11 10:44:05 ET Surrozen press release ( NASDAQ: SRZN ): Q1 GAAP EPS of -$0.48 misses by $0.07 . Cash Position: Cash, cash equivalents and marketable securities for the first quarter ended March 31, 2023 were $61.7 million, compared to $75.8 million as of Dece...
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 ...
SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Er...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 109.0% to $0.3668 on volume of 102,385,159 shares Maxeon Solar Technologies Ltd. (MAXN) rose 4.3% to $0.181 on volume of 66,422,365 shares NVIDIA Corporation (NVDA) fell 1.3% to $126.58 on volume...
Targeted protein degradation (TPD * ) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific a...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1...